MedTrace Logo

Delivra-Celecoxib 8% Cream and Osteoarthritis

NCT03698916 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2019-05-03

No results posted yet for this study

Summary

This is an observation of the current use of a transdermal preparation of Celecoxib 8% which is being used in the treatment of patients with primary OA of the knees. Subjects will be followed for 12 weeks.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

Celecoxib cream 8%

transdermal delivery of 8% Celecoxib

Sponsors & Collaborators

  • Delivra, Inc.

    collaborator INDUSTRY

  • Credit Valley Rheumatology

    lead OTHER

Principal Investigators

  • Andrew Chow, MD · Credit Valley Rheumatology

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-05-02
Completion
2019-05-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698916 on ClinicalTrials.gov